Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne N Nafziger

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacology|July 10, 2018
Opioid Therapy in Acute and Chronic PainAnne N Nafziger, Robert L Barkin
The Clinical Journal of Pain|January 23, 2009
Utility and application of urine drug testing in chronic pain management with opioidsAnne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|November 17, 2009
Desirudin dosing and monitoring in moderate renal impairmentAnne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|April 3, 2014
Seasonal influenza vaccination and technologiesAnne N Nafziger, David S Pratt
Drugs of Today (Barcelona, Spain : 1998)|November 21, 2009
Besifloxacin ophthalmic suspension for bacterial conjunctivitisAnne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|August 16, 2021
Inherent Dangers of Using Non-US Food and Drug Administration-Approved Substances of AbuseC Michael White, Thom Browne, Anne N Nafziger
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolamMaylee Chen, Anne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|January 25, 2006
Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activityLois S Lee, Joseph S Bertino, Anne N Nafziger
The American Journal of Medicine|January 9, 2003
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugsJanyce F Rogers, Anne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|April 23, 2004
Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizersJoseph D Ma, Anne N Nafziger, Joseph S Bertino
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacology|July 10, 2018
Opioid Therapy in Acute and Chronic PainAnne N Nafziger, Robert L Barkin
The Clinical Journal of Pain|January 23, 2009
Utility and application of urine drug testing in chronic pain management with opioidsAnne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|November 17, 2009
Desirudin dosing and monitoring in moderate renal impairmentAnne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|April 3, 2014
Seasonal influenza vaccination and technologiesAnne N Nafziger, David S Pratt
Drugs of Today (Barcelona, Spain : 1998)|November 21, 2009
Besifloxacin ophthalmic suspension for bacterial conjunctivitisAnne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|August 16, 2021
Inherent Dangers of Using Non-US Food and Drug Administration-Approved Substances of AbuseC Michael White, Thom Browne, Anne N Nafziger
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolamMaylee Chen, Anne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|January 25, 2006
Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activityLois S Lee, Joseph S Bertino, Anne N Nafziger
The American Journal of Medicine|January 9, 2003
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugsJanyce F Rogers, Anne N Nafziger, Joseph S Bertino
Journal of Clinical Pharmacology|April 23, 2004
Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizersJoseph D Ma, Anne N Nafziger, Joseph S Bertino
Pageof 5